Thank you. Agree, PSMA and PSA are just phenotypic markers that are demonstrably dispensable as mPC evolves under environmental and treatment selective pressure.
@craiggedye
Medical oncologist, physician/scientist #cansky #oncosky #clinicaltrials #kidneycancer #braincancer #prostatecancer #btsm #pcsm #kcsm @anzuptrials.bsky.social @COGNOtrials @iconcancercentre.bsky.social Posts my opinion only. #FCOI http://bit.ly/3xKTdPm
Thank you. Agree, PSMA and PSA are just phenotypic markers that are demonstrably dispensable as mPC evolves under environmental and treatment selective pressure.
Thank you. Could you expand? PSA response vs PSMA response - is one better?
It seems about half to two-thirds of the writers have withdrawn so it looks like it will shorter than an Ashes series... www.indailysa.com.au/news/just-in...
If anyone argues βBut what about baseload?β when you talk about renewable energy, please reference this article www.afr.com/policy/energ...
The kids have (sadly) aged out of Lego advent calendars, so thanks again to @FreseniusKabi for shipping their IV saline in such strong and repurposable cardboard boxes!
Our #HNSCC docs have implemented 'prophylactic gabapentin' based on meta-analysis showing reduced opiates and less weight loss during #chemo #radiation pmc.ncbi.nlm.nih.gov/articles/PMC...
Inferred prospective evidence from other settings? E.g. elective surgery pubmed.ncbi.nlm.nih.gov/35418085/ and peri-treatment for HNSCC www.redjournal.org/article/S036...
Grateful to have overheard a colleague talking about "preemptive pregabilin". Offered immediate upfront pregabilin for a patient with florid and painful shingles, with rapid improvement of pain. No prospective trials but interesting case series. 10/10 would Rx again. journals.lww.com/ejanaesthesi...
"Beyond respectful language, which is the minimum requirement⦠[this study] reinforces the broader message about maintaining respect for patients as individuals & ensuring that this is reflected in our words & deeds."
Β
@ascocancer.bsky.social
@jco-asco.bsky.social @ethicsdoctorp.bsky.social
It's on my bookshelf as well, and perhaps one of the only books I actually open with any regularity.
When life gives you sour mandarins...
well done and great work congrats to you and @asharpmedonc.bsky.social the team
π
Agreed. Not just HLA-A2 restricted academic.oup.com/immunotherap... maybe an efficient vaccine? onlinelibrary.wiley.com/doi/abs/10.1...
PRAME now useful as a routine phenotype IHC diagnostic marker as well, so many labs will be able to detect in routine care
NY-ESO-1?
Thanks so much to @anzuptrials.bsky.social for helping us starting putting the NZ into ANZUP - great ideas shared on the day for clinical trials for people with GU and prostate cancers in NZ and maybe also AUS as well!
Fantastic to have this critical advice for older people with cancer - thank you @crisbergerot.bsky.social @bogda-koczwara.bsky.social and team
And the infographic Research Summary as well www.nejm.org/do/10.1056/N.... Clinical trials only become healthcare if you communicate the result. Ringer's no better than saline BTW.
Online today! *Aging, Immune Fitness and Cancer* π¬ Learn the latest about the intersection between these processes in
@natrevcancer.nature.com 𧬠Great to work with
@sandramcallister.bsky.social lab again π doi.org/10.1038/s415...
One more of my votes for the #Hottest100 #TripleJ in the #Hottest200 today... The Whitlams - Blow Up The Pokies www.youtube.com/watch?v=7B49..., still as relevant today www.theguardian.com/australia-ne...
Question remains, is the abscopal effect real? Or is #RT just additive? Certainly evidence for modifying TME, intriguing data for WNT-mt patients when adding #radiotherapy to #PD1 #immunotherapy, but the idea of #RT being a 'vaccine', expanding the immune repertoire, is shown in just 1-2 patients.
The Renal IGW is fast approaching. Concept submissions close in 1 week!
Register your attendance here anzup.org.au/idea-generat...
@craiggedye.bsky.social
Two opinions that to my surprise are either unpopular or not widely held:
1. The control arm of a randomised trial should be best standard of care.
2. A PFS benefit against an inactive comparator is not a major advance, if progressive disease is required for eligibility.
3. Despite ASCO (ascopubs.org/doi/full/10....) and FDA (www.raps.org/news-and-art...) statements that it is unethical to stick large needles into people suffering cancer, many sponsors seem to want to shove large needles into people suffering cancer; for what? To make pretty pictures for a poster?
Great kickoff to clinical trials workshop #ANZUP25 β #MelissaLeMesurier w patient perspective and #ChrisGianacas biostats on collaborative efforts for clinical trials. Same global themes for clinical trial development. @anzuptrials.bsky.social @craiggedye.bsky.social @profiand.bsky.social
Tremendous insights with immediate patient impact; using genomic data we can collect routinely from today's patients, we may be able to predict upfront resistance, rather than subject people to 3-4 cycles of chemo, and we might also be strategic if we know people have sensitive cancers - bravo!
Bravo. Fantastic news.
Friends, I have news.
It is very good news.
You'll just have to read it, I'm afraid.
jamesclaims.substack.com/p/introducin...